

Table 1b. Antibody Performance, Weeks 1 and 2 – IgG

IgG	Week 1			Week 2		
Sensitivity	0.23 (95% CI: 0.16 to 0.32)			0.68 (95% CI: 0.62 to 0.73)		
Specificity	0.99 (95% CI: 0.99 to 0.99)					
Outcome	Effect per 1,000 patients tested					
	pre-test probability of 1% ^a	pre-test probability of 10% ^b	pre-test probability of 40% ^c	pre-test probability of 1% ^a	pre-test probability of 10% ^b	pre-test probability of 40% ^c
True positives (patients with COVID-19)	2 (2 to 3)	23 (16 to 32)	92 (64 to 128)	7 (6 to 7)	68 (62 to 73)	272 (248 to 292)
False negatives (patients incorrectly classified as not having COVID-19)	8 (7 to 8)	77 (68 to 84)	308 (272 to 336)	3 (3 to 4)	32 (27 to 38)	128 (108 to 152)
Quality of the evidence	13 studies, 1343 patients ⊕○○○ VERY LOW ^{d,e}			16 studies, 2708 patients ⊕⊕○○ LOW ^{d,e}		
	pre-test probability of 1% ^a		pre-test probability of 10% ^b		pre-test probability of 40% ^c	
True negatives (patients without COVID-19)	980 (980 to 980)		891 (891 to 891)		594 (594 to 594)	
False positives (patients incorrectly classified as having COVID-19)	10 (10 to 10)		9 (9 to 9)		6 (6 to 6)	
Quality of Evidence	25 studies, 11887 patients ⊕⊕⊕○ MODERATE ^d					

a. Typically seen in general population in areas that are not hotspots

b. Typically seen in general population in high risk populations

c. Typically seen in general population in exposed and nursing homes

d. The case-control design leads to a serious risk of bias

e. Unexplained inconsistency observed with considerably variable sensitivity. Sensitivity Ranges: C1: 0.00,0.69, C2: 0.27-0.91